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PERSPECTIVE
Inﬂ  uenza A (H5N1) viruses are strong candidates for 
causing the next inﬂ   uenza pandemic if they acquire the 
ability for efﬁ  cient human-to-human transmission. A major 
public health goal is to make efﬁ  cacious vaccines against 
these viruses by using novel approaches, including cell-cul-
ture system, reverse genetics, and adjuvant development. 
Important consideration for the strategy includes prepara-
tion of vaccines from a currently circulating strain to induce 
broad-spectrum immunity toward newly emerged human 
H5 strains. This strategy would be a good solution early in a 
pandemic until an antigenically matched and approved vac-
cine is produced. The concept of therapeutic vaccines (e.g., 
antidisease vaccine) directed at diminishing the cytokine 
storm frequently seen in subtype H5N1–infected persons is 
underscored. Better understanding of host–virus interaction 
is essential to identify tools to produce effective vaccines 
against inﬂ  uenza (H5N1).
B
ird ﬂ  u caused by the inﬂ  uenza A virus subtype H5N1 
has spread with alarming speed across Europe, Africa, 
and parts of Asia in which the infection was not report-
ed earlier. Establishment of the highly pathogenic avian 
inﬂ  uenza (H5N1) as an endemic virus within duck and 
poultry populations and its capacity to cross species barri-
ers increase the possibility of adaptation to humans and a 
pandemic. Human inﬂ  uenza infections with subtype H5N1 
viruses are often fatal. As of June 4, 2007, 309 laboratory-
conﬁ  rmed cases of human infection have been reported to 
the World Health Organization (WHO); 61% were fatal, 
mainly in persons 10–39 years of age (www.who.int/csr/
caculatordisease/avian_inﬂ  uenza/en). If a pandemic is trig-
gered by transmissibility of inﬂ  uenza (H5N1) from person 
to person, millions of people could die, and economies 
would likely be crippled for 6–24 months.
In the event of a pandemic, vaccination against inﬂ  u-
enza (H5N1) could limit the impact of infection at a public 
health level. However, no evidence exists that available 
vaccines would be protective against the pandemic strain 
of the virus. We comment on some of the limitations of 
currently available vaccines and propose novel strategies to 
improve vaccine formulations against inﬂ  uenza (H5N1). 
Host’s Immune Responses to Inﬂ  uenza (H5N1)
The host response to inﬂ  uenza (H5N1) infection has 
not been deﬁ  ned, which has proven a considerable chal-
lenge in epidemiology and public health research. To devel-
op efﬁ  cient vaccines, understanding how the virus interacts 
with the host in natural infection is necessary. Having in-
sights into the hosts’ responses to inﬂ  uenza (H5N1) would 
help deﬁ  ne targets for therapeutic intervention. Whether 
humans can develop immunity during a primary infection 
that would control replication and spread of subtype H5N1 
viruses has been questioned (1). However, marked inﬂ  am-
matory responses develop after infection with inﬂ  uenza 
(H5N1) in humans and other animals (2–4). This condi-
tion is associated with statistically signiﬁ  cant synthesis of 
various proinﬂ  ammatory cytokines, such as tumor necrosis 
factor-α, interleukin (IL)–6, interferon (IFN)-γ, IL-1α, and 
chemokines, including IP-10, MIG, monocyte chemoat-
tractant protein–1 (MCP-1, IL-8, and RANTES. i.e., regu-
lated on activation, normal T-cell expressed and secreted). 
If this is the case, these observations are consistent with 
the possible induction of innate immune responsiveness in 
the persons infected with inﬂ  uenza (H5N1). Most cases of 
inﬂ  uenza (H5N1) infection in humans have been described 
as clinical. However, whether subclinical or asymptomatic 
infections can develop in some persons is not known. Dis-
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ease in humans caused by inﬂ  uenza (H5N1) appeared to 
be milder in Turkey than in eastern Asia (5). The death 
rate of ≈25% was half that of previously known outbreaks, 
and 5 mild or completely asymptomatic cases have been 
reported. One theory holds that milder cases have been oc-
curring elsewhere but are not being recorded. Recently, 3 
persons among 120 apparently healthy volunteers from the 
People’s Republic of China, showed detectable virus-neu-
tralizing antibody response to subtype H5N1 before vac-
cination (6). Moreover, pigs infected with subtype H5N1 
have become asymptomatic in Indonesia. Are these signs 
of development of some degree of immunity to virus, con-
taining its replication and thus causing milder infection in 
naturally infected mammals? 
Recently, clusters of bird ﬂ  u cases were reported in 
Western Java, Indonesia (7); fatal disease developed in 
6 persons there from the same family. Two other family 
members became ill but survived. All the family members 
likely had similar levels of exposure because they all lived 
in the same household. Other cases of nonfatal infections 
have been seen in Thailand and Vietnam. Unfortunately, 
there is little information about the immune response to the 
virus in those who survived, which would be valuable for 
understanding the mechanisms of protection. Indeed, fol-
lowing up the persons (cohort) living in the same affected 
villages, presumably mostly not exposed to virus, should 
clarify whether the maintained response reﬂ  ects boosting 
through natural exposure. Persons with prior exposure, as 
measured by antibody or viral RNA at recruitment, would 
likely have substantially higher responses to the vaccine 
than those naïve at recruitment if the vaccinating antigen 
contains homologous or cross-reacting determinants. Con-
ceivably, boosting the “natural” immunity is a desirable 
outcome to improve protective efﬁ   cacy of any vaccine 
approach. Additional studies are required to evaluate the 
merits of priming populations in advance of an inﬂ  uenza 
(H5N1) pandemic.
After initial hesitation about using a wide-scale pro-
gram of poultry vaccination, some European and Asian 
countries have begun vaccination. Inactivated vaccines are 
widely used in poultry but lack of critical potency testing, 
standardization, and quality control has led to variable and 
suboptimal immune responses. Moreover, a legitimate con-
cern remains that the fowl vaccinated by attenuated live vi-
ruses may survive the disease but still carry the virus; thus, 
they would continue to spread inﬂ  uenza (H5N1) silently at 
the ﬂ  ock level (8) or to humans who come into contact with 
them. Vaccination that resulted in low levels of seroconver-
sion facilitated the emergence of the Fujian-like sublineage 
of inﬂ  uenza (H5N1) in poultry (9). 
The immune responses elicited by subpotent vaccines 
may exert selection pressure that favors antigenic drift and 
shift (Figure). Antigenic drift relies on the accumulation of 
mutations within the antibody-binding sites in the hemag-
glutinin (HA), neuraminidase (NA), or both that abrogate 
the binding of antibodies. This makes inﬂ  uenza A virus 
strains able to evade neutralizing antibody from prior in-
fection or vaccination. Antigenic shift, which is seen only 
with inﬂ  uenza A viruses, is a more drastic change. It results 
from genetic shift by reassortment exchange of the HA, and 
sometimes the NA, with novel subtypes that have not been 
present in human viruses for a long time. Antigenic shift 
leads to replacement of circulating strains with new vari-
ants that are able to reinfect hosts immune to earlier types; 
the result is usually a pandemic. Antigenic shifts caused 
2 of the major inﬂ  uenza A pandemics in the last century, 
including the 1957 subtype H2N2 and 1968 subtype H3N2 
outbreaks (10).
Live Vaccines for Use in Humans
Most inﬂ  uenza vaccines used in the United States and 
Europe are produced in embryonated hens’ eggs and are 
formaldehyde-inactivated preparations (11). Because high-
ly pathogenic inﬂ  uenza (H5N1) subtypes may kill embryo-
nated eggs, use of viruses that are no longer pathogenic, 
such as H5 (which lacks the polybasic cleavage site), to 
reduce the virulence of inﬂ  uenza (H5N1) vaccine strains so 
that these can be efﬁ  ciently propagated in eggs for vaccine 
production is feasible (10). Virus particles that lack the gene 
for the nuclear export protein or are defective for the ma-
trix (M2) gene were used as live vaccines in animal models 
(12,13); however, whether these replication-defective vac-
cines will work in humans is not known. Live attenuated 
(cold-adapted) inﬂ  uenza vaccines have long been used in 
Russia, and a similar product has been approved for use in 
the United States (14). These vaccines will replicate in the 
host, and thus lower doses may be effective; however, the 
Figure. Spreading mode of inﬂ  uenza A (H5N1) viruses and efforts 
to make better vaccines for potential pandemic.  ARDS, acute 
respiratory distress syndrome.
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preexisting antibody to the virus is more likely to diminish 
the value of a live vaccine. Moreover, such live vaccines 
are reported to cause asthma-like reactivity in children (15). 
Monitoring live inﬂ  uenza vaccines is important because the 
risk for reversion to pathogenicity remains.
With the use of a technique known as reverse genetics, 
a prototype of inﬂ  uenza virus (H5N1) has been produced for 
the development of an inactivated subvirion vaccine. The 
gene segments encoding HA and NA were derived from 
A/Vietnam/2004, and all other genes were derived from the 
backbone (A/PR/8/34) virus, commonly used as a platform 
for inﬂ  uenza vaccine production. The HA gene was further 
modiﬁ  ed to replace the stretch of 6 basic amino acids at the 
cleavage site, and the resulting virus was avirulent in chick-
ens. In a recent trial, healthy adult volunteers were given 2 
intramuscular doses of this inactivated inﬂ  uenza (H5N1) 
vaccine. This split vaccine induced an antibody response 
predictive of protection in 54% of healthy adults tested, but 
only when given intramuscularly at high doses (two 90-μg 
shots) (16). The large amounts needed (2 doses of vaccine, 
each 6 times the dosage of that used in a standard inﬂ  uenza 
shot) means that hundreds of millions of doses are needed 
to tackle a pandemic. Dose-sparing approaches, including 
the use of an efﬁ  cient nontoxic adjuvant to boost persons’ 
immune responses, may improve the vaccine. Another trial 
was performed with 300 healthy participants 18–40 years 
of age, in which aluminum hydroxide adjuvant was used 
with similar split-virus vaccine (17). However, the alum-
adjuvanted vaccines did not improve the immunogenicity 
or percentage of seroconversion at lower vaccine doses 
and only slightly improved immunogenicity at the 30-μg 
dose. This difﬁ  culty underscores the importance of vigor-
ous fundamental research to address the question of how 
to increase the immunogenicity of such vaccines, whether 
by better antigen presentation or by choosing alternative 
routes of administration, so that lesser amount of antigen 
could be given to induce protective response. The present 
annual global production capacity is ≈300 million doses of 
trivalent vaccine containing 15 μg HA per strain. This is 
equivalent to 900 million doses of monovalent vaccine, a 
quantity markedly insufﬁ  cient for the world’s 6.5 billion 
people. Clearly, dose-sparing formulations are urgently 
needed.
Inactivated Vaccines for Immunizing Humans
To test the hypothesis that whole-virion would be 
more immunogenic than conventional split-virion or sub-
unit vaccines and may be adaptable to the antigen-sparing 
strategy, an inactivated, monovalent inﬂ  uenza A (H5N1), 
whole-virion vaccine was prepared from a highly virulent 
strain A/Vietnam/1194/2004 strain by removing the poly-
basic amino acids at the cleavage site, making the virus no 
longer pathogenic. The seed virus was grown to a high titer 
in embryonated eggs, inactivated with formalin, and puri-
ﬁ  ed. These viruses were then adjuvanted with aluminum 
hydroxide and used in a phase 1 trial (6). The highest im-
mune response of 78% seropositivity was observed in the 
group given 2× 10 μg HA, which is equivalent to that elicit-
ed by higher doses of nonadjuvanted (90 μg) or adjuvanted 
(30 μg) split-virion vaccines (16,17).
Not knowing which particular genetic variant will 
sustain human-to-human transmission makes our ability to 
formulate a vaccine in advance all the more difﬁ  cult. An 
inactivated vaccine that induces not only high levels of 
neutralizing antibody to surface proteins but also CD8 T-
cell response against well-conserved antigens derived from 
internal viral proteins might provide superior protection in 
an epidemic or pandemic. In cases of established intracel-
lular inﬂ  uenza A infection, infected cells are mainly elimi-
nated by effector CD8+ T cells (CTLs) (18). Any vaccine 
that will induce and direct these CTLs to the site of infec-
tion and generate a long-lasting memory response will be 
more effective for mounting protection against a pandemic 
form of inﬂ  uenza (H5N1). Inactivated vaccines need to be 
presented to the host’s immune system with an appropri-
ate adjuvant, but inactivated vaccines that use an adjuvant 
currently approved for human use (alum or MF-59) usually 
have lower immunogenicity than live attenuated vaccines 
(10). Therefore, the pursuit for other nontoxic adjuvants, 
including TLR ligands and agonists that could effectively 
activate dendritic cells for the presentation of viral antigens 
to CD4 and CD8 T cells, should vigorously be continued. 
Use of cytokines such as IL-12 or IL-18 may enhance 
the immunogenicity of antiviral vaccines. Recombinant 
fowlpox vaccines coexpressing HA of subtype H5N1 and 
chicken IL-18 have been shown to induce complete pro-
tection in vaccinated chickens (19). Use of adjuvants may 
enhance broader cross-reactive immune responses among 
inﬂ  uenza viruses (20).
Vaccines that Generate Broad-spectrum Immunity
The evolution of many sublineages of inﬂ  uenza 
(H5N1) with antigenic diversity in Southeast Asia and 
southern China favors the wisdom of developing broadly 
cross-reactive vaccines for protection against an epidemic 
or pandemic (21). Genetically engineered viruses could be 
constructed; these would express several variant antigens 
or determinants, thereby generating a broader immune re-
sponse. The goal would be to develop vaccines that would 
induce broad-spectrum immunity-conferring protection 
to inﬂ  uenza including subtype H5N1. Ferrets vaccinated 
with A/PR/8/34 single-gene reassortants that differed only 
in their H5s were protected against a lethal challenge with 
A/Vietnam/1203/04 virus, suggesting generation of cross-
protection (22). Vaccination of mice with a live attenuated 
inﬂ  uenza vaccine or an alum-adjuvanted inactivated inﬂ  u-
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enza vaccine based on a related H5 HA from a nonpatho-
genic avian inﬂ  uenza virus, A/Duck/Pottsdam/1042–6/86 
(H5N2), limited the disease severity and reduced deaths 
following challenge with a current highly pathogenic in-
ﬂ  uenza (H5N1) (23). Such cross-protective vaccines may 
provide clinical protection and prevent deaths in the early 
stages of a pandemic.
Genes of highly conserved proteins such as the nu-
cleoprotein or M2 proteins could be included in adenovirus 
vector–based vaccines because immune responses against 
these inﬂ  uenza viral antigens provide protection in animal 
models (24,25). Recently, human adenoviral vector–based 
HA subtype 5 inﬂ  uenza vaccine induced protection in mice 
against inﬂ   uenza (H5N1) viruses isolated from humans 
(26,27). However, pre-existing immune response to human 
adenoviruses could be a potential problem in the genera-
tion of immune response against a foreign gene of interest. 
Delivering the vaccine nasally could largely overcome this 
problem because there appears to be no pre-existing immu-
nity in the upper airways. Moreover, a robust CD8 T-cell 
response would likely be ﬂ  exible and able to ﬁ  ght inﬂ  uenza 
(H5N1).
Ideally, we need an effective vaccine for persons of all 
ages. However, if the vaccine is in short supply, priming 
ﬁ  rst those persons at high risk (e.g., young children, per-
sons >50 years of age, healthcare workers) may be justiﬁ  -
able. During the early stages of an emerging H5 pandemic, 
such persons at high risk might be given an adjuvanted vac-
cine produced from a currently circulating strain, even if 
it is antigenically distinct, until an optimally matched and 
approved vaccine is available. This strategy is to produce 
a vaccine from an antigenically distant inﬂ  uenza (H5N1) 
strain that could induce broad-spectrum immunity capable 
of neutralizing newly emerged human H5 strains.
Cell Culture–based Vaccines
Vaccine development based on a cell culture system 
has advantages over egg-based technology because H5 
strains are highly pathogenic for chickens and supplying 
large numbers of embryonated eggs could be difﬁ  cult in a 
pandemic. In addition, potential allergic reactions to egg 
components would be avoided by growing the vaccine vi-
rus in tissue culture cells. Recently, mammalian cell culture 
was used for propagating viruses to prepare killed inﬂ  u-
enza vaccine (28). Inactivated inﬂ  uenza vaccines produced 
with Madin-Darby canine kidney (MDCK) and Vero cells, 
which served as vaccine substrates, have been licensed in 
the Netherlands. Of note, the human cell line PER.C6 may 
provide a useful cell-based system because, unlike MDCK 
and Vero cell systems, it does not require a solid matrix 
support for the growth of cells. Selecting background vi-
ruses that grow well in these cell cultures and monitoring 
them for antigenic changes and contaminating microbes 
during propagation of the virus in cell culture need to be 
considered.
Development of “Universal” Vaccines
For the development of a universal inﬂ  uenza vaccine, 
a possible target is the relatively conserved M2 homo-
tetramer. The concept is based on identifying alternative 
inﬂ  uenza antigens that are not as susceptible to antigenic 
shift and drift. Some degree of protection was induced in 
mice by priming with an M2 ectodomain peptide in adju-
vant (29). Studies that used the M2eA peptide conjugated 
to keyhole limpet hemocyanin and Neisseria meningitidis 
outer membrane protein illustrated good immune responses 
not only in mice but also in ferrets and rhesus monkeys 
(30). In a recent study, 3 M2eA sequences, representing a 
range of epidemic strains and the (H5N1) strain, were fused 
to a proprietary hydrophobic protein domain. The resulting 
fusion proteins, formulated in liposomes, stimulated a pro-
tective response in mice challenged with subtypes H1N1, 
H5N1, H6N2, or H9N2 (31). Previous studies have shown 
that when M2e is linked to hepatitis B virus core (HBc) 
particles, it becomes highly immunogenic, eliciting protec-
tive antibody response in mice (25). Recently, a series of 
M2e–HBc constructs were made by increasing the copy 
number of M2e inserted at the N terminus from 1 to 3 per 
monomer. The best protection was seen when mice were 
vaccinated intranasally with these constructs combined 
with CTA1-DD, a cholera toxin A1–derived mucosal ad-
juvant (32).
M2 serves as a pH-induced proton channel on the sur-
face of all inﬂ  uenza A viruses but is present in low quan-
tities. Further studies are warranted for understanding the 
mechanism of immune response to M2eA and for deﬁ  ning 
the appropriate immunization conditions for humans.
Vaccination and Correlates of Immune Protection
The lack of established correlates of immunity in ani-
mals and humans poses challenges to developing consistent 
immunologic endpoints for clinical trials and appropriate 
criteria for vaccine efﬁ  cacy. Serum antibody titers, mainly 
those determined by hemagglutination inhibition (HI) or 
virus neutralization (VN) assays, or both, are considered 
surrogate measures of protection. However, the HI test is 
insensitive for the detection of antibody to avian HA; there 
also are no recognized clinical correlates of immune pro-
tection for neutralization antibody (33,34). Recently, HI or 
VN assay failed to detect antibodies in ferrets protected by 
vaccination with whole-virus vaccines containing internal 
protein from Dk/Sing virus against a heterotypic virus (34). 
Whether the cross-protection reported is mediated by T-
cell response is not known.
In recent years, attempts were made to improve the 
sensitivity of the HI test. More sensitive detection of anti-
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body to avian HA was seen when horse erythrocytes were 
used in place of turkey erythrocytes in the HI test because 
inﬂ  uenza virus was better able to bind to a2,3Gal-speciﬁ  c 
receptor sites on these erythrocytes (35). The presence of 
asparagines at aa223 (H5 numbering) in H5 HA leads to 
improved sensitivity of the HI test (22).
Often the immunogenicity of H5 vaccine candidates 
is assessed by HI or VN assays, but the basis of protec-
tion remains unclear. Nevertheless, the tests that are used 
to evaluate efﬁ  cacy of candidate vaccines are based on the 
assumption that antibody would mediate the protection 
against infection induced by vaccination, although this has 
yet to be critically established.
On the basis of initial evidence, inﬂ  ammation has been 
proposed as a possible cause or driving force of avian in-
ﬂ  uenza (H5N1). However, components of the inﬂ  amma-
tory response might even be beneﬁ  cial. To address these 
possibilities, we need to determine whether inﬂ  ammation 
in avian inﬂ  uenza is an early event and a manifestation of 
innate immune response. If it is, some of the mediators 
of innate immune response, such as cytokine/chemokine 
levels, can be included in the evaluation of the potency of 
candidate vaccines. Further humoral response as a corre-
late for protection can be ﬁ  ne-tuned by determining the titer 
and isotype of antibody after vaccination. Several issues 
concerning vaccine efﬁ  cacy are unresolved: What are the 
consequences of vaccination for existing inﬂ  uenza (H5N1) 
infection, the extent of serologic cross-reactivity between 
the most closely related types of the virus, and the role in 
clinical protection? Vaccine administration may provide 
some therapeutic effects for infected persons who have not 
yet made an immune response but provide none for those 
with persistent infection associated with measurable hu-
moral immunity.
Clearly, more studies are warranted to establish a high-
ly reproducible assay to measure immunogenicity of a can-
didate vaccine and to determine adequate correlates of im-
mune protection. Safety and immunogenicity of adjuvanted 
vaccines or new formulations should be critically assessed, 
and any fast-track approval of marketing vaccines must not 
compromise safety.
Development of Therapeutic 
(Antidisease) Vaccines
The marked virulence of the 1997 outbreak suggests 
that inﬂ  uenza A (H5N1) infection may have novel patho-
genic mechanisms not seen in human inﬂ  uenza strains. To 
attempt to understand pathogenicity of this virus, an inﬂ  u-
enza virus bearing all 8 gene segments of the 1918 pan-
demic virus, which claimed at least 20–40 million lives, 
was recently generated in cultured cells. The reconstructed 
1918 inﬂ  uenza viruses displayed accelerated activation of 
host immune response in mice with high levels of chemo-
kines and cytokines in the lungs, resulting in inﬁ  ltration of 
inﬂ  ammatory cells and extensive damage to the lungs with 
severe hemorrhaging (36). The pathogenicity induced by 
the reconstructed virus showed marked similarity to that 
reported with inﬂ  uenza (H5N1).
Increasing evidence from mouse models and humans 
suggests that certain inﬂ  ammatory mediators are potent 
drivers of the disease. If this is true, this could have impor-
tant implications for developing new therapeutics. Acute 
respiratory distress syndrome, hemophagocytosis, or both, 
develop in a substantial fraction of patients with inﬂ  uenza 
(H5N1) infection; both of these conditions are thought to be 
promoted by overproduction of proinﬂ  ammatory cytokines 
(known as a “cytokine storm”) (37). Consistent with these 
observations, cytokine release was markedly enhanced in 
human macrophages after infection with inﬂ  uenza (H5N1) 
(38). Further, marked enhancement of chemokine and cyto-
kine levels was observed in inﬂ  uenza (H5N1)–infected per-
sons, particularly in those who died, and these correlated 
with high and disseminated viral replication (4). Addition-
ally, inﬂ  uenza (H5N1) viruses appear relatively resistant 
to the inhibitory effects of host antiviral cytokines, such as 
interferons (IFNs) (39). Thus, the severity of human inﬂ  u-
enza (H5N1) infection may be related to the induction of 
excessive proinﬂ  ammatory responses that can accompany 
a primary infection and high viral shedding. Increased in-
ﬂ  ammation was associated with viral replication in the re-
spiratory and extrarespiratory organs of cats experimentally 
infected with inﬂ  uenza (H5N1) (3). Mice infected with the 
highly pathogenic inﬂ  uenza (H5N1) strain A/HK/156/97, 
originally obtained from diseased chickens and an ill child 
in Hong Kong, China (HK), showed reduced ability to ac-
tivate transforming growth factor–β (TGF-β), a potent anti-
inﬂ  ammatory cytokine, compared to mice infected with 
less virulent A/Env/HK437/99 viruses (2). The reduced 
ability to activate TGF-β may produce greater inﬂ  amma-
tion at the site of infection and thus cause more severe 
disease. Alternatively, the low levels of activated TGF-β 
in the sera of A/HK/156/97-infected mice may allow the 
viruses to replicate and spread unchecked in the respiratory 
tracts of the mice, causing more severe disease. Recently, 
the impact of the nonstructural (NS) gene variation of Hong 
Kong (H5N1)/97 on cytokine production was illustrated 
(40). The NS gene reassortant induced elevated pulmonary 
concentrations of the inﬂ  ammatory cytokines IL-1α, IL-1β, 
IL-6, IFN-γ, and chemokine KC and decreased concentra-
tions of the anti-inﬂ  ammatory cytokine IL-10. This cyto-
kine imbalance is reminiscent of the clinical ﬁ  ndings in 
humans infected with inﬂ  uenza (H5N1)/97 virus and may 
explain the unusual severity of the disease. 
The ability to site speciﬁ  c engineering changes in the 
virus genome allows us to consider a novel vaccine ap-
proach. By engineering a virus with site-speciﬁ  c changes 
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in the genome (for example in NS gene), we may pro-
duce inﬂ  uenza virus vaccine that favors the production of 
beneﬁ  cial anti-inﬂ  ammatory cytokines but remains highly 
immunogenic. In another approach, a human replication-
incompetent, adenoviral vector–based inﬂ  uenza vaccine 
could be developed, in which genes of anti-inﬂ  ammatory 
cytokines are coexpressed, which will inhibit overproduc-
tion of proinﬂ  ammatory cytokines. Such vaccines would 
be considered therapeutic vaccines (e.g., antidisease 
vaccines), which would inhibit inﬂ  ammation at the site 
of infection and protect against severe disease (Figure). 
Excessive production of anti-inﬂ  ammatory cytokines may 
result in an inappropriate suppression of the host immune 
response. Further studies will validate the beneﬁ  cial ef-
fect of the anti-inﬂ  ammatory response for temporizing the 
cytokine storm seen in inﬂ  uenza (H5N1). Development 
of an immunization protocol that uses an adjuvant that 
allows selective priming of an antigen-speciﬁ  c immuno-
regulatory cytokines (e.g., IL-10, TGF-β) would be a ma-
jor advance in the development of a vaccine for bird ﬂ  u 
with a substantial inﬂ  ammatory component. The search 
for potential adjuvants, such as TLR ligands and agonists 
that will favor the synthesis of inhibitory cytokines in-
cluding IL-10, should be pursued. By testing whether ma-
nipulation of inﬂ  ammatory pathways changes the patho-
logic course, we would identify new targets for disease 
intervention.
Conclusions
Vaccination is the best option by which to prevent 
the spread of a pandemic virus and reduce the severity of 
disease. Deﬁ  ning the host response to inﬂ  uenza (H5N1) in 
natural infection is urgently needed to better understand 
the basis of protection and subsequent development of ef-
ﬁ  cacious vaccines. Improved vaccine strategies, which will 
require less antigen and be more robust in inducing both 
antibody and cell-mediated immunity for neutralizing in-
ﬂ  uenza (H5N1) viruses, should be considered. To create 
an effective vaccine, a combination of factors must be op-
timized—such as number of doses, formulation without 
or with better adjuvant, and dose range. We also need to 
develop a reproducible assay that measures immunoge-
nicity of a vaccine and to establish adequate correlates of 
protection. The efﬁ  cacy of potential cross-reactive vaccine 
candidates to induce broad-spectrum immunity to inﬂ  uenza 
(H5N1) viruses should be assessed critically; stockpiling 
of such vaccines may be justiﬁ  ed in the absence of opti-
mally matched and approved vaccine during early stages 
of an H5 pandemic. Search for therapeutic vaccines (anti-
disease vaccines) aimed at controlling innate immune re-
sponses should be pursued, given the clinical evidence that 
the H5N1 subtype elicits a cytokine storm that contributes 
to disease pathogenesis. Vaccine development and deploy-
ment need to be undertaken by a partnership of academia, 
government, and industry. The risk for dissemination of 
pandemic virus will remain if the disease is controlled in 1 
area but not in others. A global approach is vital for com-
bating the next inﬂ  uenza pandemic, a monumental public 
health challenge.
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